Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
Further Publications Urology
Related content
Uro-Oncology
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review
Eur Urol
Weiner AB, Kakani P, Armstrong AJ, Bossi A, Cornford P, Feng F, Kanabur P, Karnes RJ, Mckay RR, Morgan TM, Schaeffer EM, Shore N, Tree AC, Spratt DE
doi: 10.1016/j.eururo.2024.04.034
Uro-Oncology
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Eur Urol
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR
doi: 10.1016/j.eururo.2024.03.036
Uro-Oncology
Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Eur Urol
Roy S, Fervaha G, Spratt DE, Sun Y, Kishan AU, Loblaw A, Malone S, Ong M, Saad F, Wallis CJD, Morgan SC
doi: 10.1016/j.eururo.2024.03.018
Uro-Oncology
Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial
J Urol
Bahler CD, Tachibana I, Tann M, Collins K, Swensson JK, Green MA, Mathias CJ, Tong Y, Yong C, Boris RS, Brocken E, Hutchins GD, Sims JB, Hill DV, Smith N, Ferari C, Love H, Koch MO
doi: 10.1097/JU.0000000000004032
Uro-Oncology
Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies
Prostate Cancer Prostatic Dis
Falagario UG, Pellegrino F, Fanelli A, Guzzi F, Bartoletti R, Cash H, Pavlovich C, Emberton M, Carrieri G, Giannarini G
doi: 10.1038/s41391-024-00827-x
Uro-Oncology
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Prostate Cancer Prostatic Dis
George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ
doi: 10.1038/s41391-024-00816-0
Uro-Oncology
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe
Eur Urol
Vynckier P, Annemans L, Raes S, Amrouch C, Lindgren P, Májek O, Beyer K, Leenen RCA, Venderbos LDF, Denijs F, van Harten MJ, Helleman J, Chloupková R, Briers E, Vasilyeva V, Rivas JG, Basu P, Chandran A, van den Bergh RCN, Collen S, Van Poppel H, Roobol MJ, members of the PRAISE-U Consortium
doi: 10.1016/j.eururo.2024.04.036
COMMENTED
Uro-Oncology
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Freedland SJ, Mulhall JP, Gleave M, Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N
doi: 10.1016/j.eururo.2025.02.006
Benign Prostatic Hyperplasia (BPH)
Transperineal laser ablation in the management of benign prostatic hyperplasia: an updated systematic review and pooled analysis
Prostate Cancer Prostatic Dis
Alberti A, Lo Re M, Nicoletti R, Polverino P, Cadenar A, Ciaralli E, Solazzi F, Giustozzi B, Sessa F, Rivetti A, Campi R, Sebastianelli A, Serni S, Gacci M
doi: 10.1038/s41391-025-00952-1